Cardiff Oncology Inc
CRDF
查看详细走势图
2.920USD
+0.350+13.62%
收盘 12/22, 16:00（美东）报价延迟15分钟
195.92M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+13.62%
5天
+22.18%
1月
+43.84%
6月
-5.81%
今年开始到现在
-32.72%
1年
-31.46%
查看详细走势图
TradingKey Cardiff Oncology Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Cardiff Oncology Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名96/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价10.42。中期看，股价处于上升通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cardiff Oncology Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
8
位分析师
买入
评级
10.417
目标均价
+345.16%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cardiff Oncology Inc亮点
亮点风险
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
业绩高增长
公司营业收入稳步增长，连续3年增长76.94%
业绩增长期
公司处于发展阶段，最新年度总收入683.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入683.00K美元
估值低估
公司最新PE估值-3.24，处于3年历史低位
机构减仓
最新机构持股23.08M股，环比减少0.00%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值5.84K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.06
Cardiff Oncology Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cardiff Oncology Inc简介
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
公司代码CRDF
公司Cardiff Oncology Inc
CEOErlander (Mark)
网址https://cardiffoncology.com/
常见问题
Cardiff Oncology Inc(CRDF)的当前股价是多少？
Cardiff Oncology Inc(CRDF)的当前股价是 2.920。
Cardiff Oncology Inc的股票代码是什么？
Cardiff Oncology Inc的股票代码是CRDF。
Cardiff Oncology Inc股票的52周最高点是多少？
Cardiff Oncology Inc股票的52周最高点是4.990。
Cardiff Oncology Inc股票的52周最低点是多少？
Cardiff Oncology Inc股票的52周最低点是1.900。
Cardiff Oncology Inc的市值是多少？
Cardiff Oncology Inc的市值是195.92M。
Cardiff Oncology Inc的净利润是多少？
Cardiff Oncology Inc的净利润为-45.45M。
现在Cardiff Oncology Inc(CRDF)的股票是买入、持有还是卖出？
根据分析师评级，Cardiff Oncology Inc(CRDF)的总体评级为买入，目标价格为10.417。
Cardiff Oncology Inc(CRDF)股票的每股收益（EPS TTM）是多少
Cardiff Oncology Inc(CRDF)股票的每股收益（EPS TTM）是-0.793。
相关品种
